PRAC2: A Non-Code RNA Molecule Regulating Stem Cell Self-Renewal and Cancer Progression

Target Name: PRAC2

NCBI ID: G360205

PRAC2

PRAC2: A Non-Code RNA Molecule Regulating Stem Cell Self-Renewal and Cancer Progression

PRAC2, also known as HOXB13 antisense RNA 1 (non-protein coding), is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. The HOX gene family is a well-known gene family that is involved in the regulation of cell growth, differentiation, and transformation. The HOXB13 gene is a non-coding RNA molecule that has been shown to play a role in the regulation of the stem cell self-renewal process.

PRAC2 is a non-coding RNA molecule that is derived from the HOXB13 gene. It is characterized by the presence of a non-coding RNA molecule that contains 79 amino acid residues. PRAC2 is expressed in a variety of tissues, including human pluripotent stem cells, mouse embryonic stem cells, and human cancer cells.

PRAC2 has been shown to play a role in the regulation of stem cell self-renewal. Stem cells are a type of cell that have the ability to self-renew and differentiate into any cell type in the body. PRAC2 has been shown to promote the self-renewal process by regulating the expression of genes that are involved in cell growth and differentiation.

In addition to its role in stem cell self-renewal, PRAC2 has also been shown to play a role in the regulation of cellular processes that are important for cancer progression. For example, PRAC2 has been shown to promote the migration of cancer cells by regulating the activity of the protein tyrosine kinase (PTK).

PRAC2 is also a potential drug target because of its involvement in the regulation of cellular processes that are important for cancer progression. inhibiting the activity of PRAC2 could potentially be a useful therapy for the treatment of certain types of cancer.

In conclusion, PRAC2 is a non-coding RNA molecule that has been shown to play a role in the regulation of stem cell self-renewal and the regulation of cellular processes that are important for cancer progression. As a potential drug target, PRAC2 is a promising target for the development of new therapies for the treatment of cancer. Further research is needed to fully understand the role of PRAC2 in cellular processes and its potential as a drug target.

Protein Name: PRAC2 Small Nuclear Protein

The "PRAC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets